London, United Kingdom
GENZ Biotechnology, headquartered in the United Kingdom, is making significant strides in the AI, Biotechnology, and Health Care industries. Founded in 2017, the company operates as a spin-off focused on developing novel solutions from in vitro diagnostics to therapeutics. With the slogan “Developing novel IVD solutions,” GENZ aims to provide innovative, affordable, and accessible diagnostics while contributing to sustainable growth.
So far, GENZ has successfully commercialized four IVD diagnostic tests. The company's strategic collaborations with leading research centers globally and its participation in international joint projects emphasize its commitment to cutting-edge scientific research. Furthermore, several articles published in international journals showcase their contributions to advancing the field.
The last investment in August 2020 amounted to $100.00K in a Seed Round, with participation from renowned investors like RTA Capital, Erdem Gülen, and Ebru Dorman. GENZ Biotechnology presents a robust opportunity for investors seeking to back a company addressing crucial health challenges with a promise of high impact and value creation.
GenePath Diagnostics